Drugs for Tuberculosis
JB Nachega and RE Chaisson. Tuberculosis drug resistance: a global threat. Clin Infect Dis 2003; 36 suppl 1:S24.
JS Mukherjee et al. Programmes and principles in treatment of mul- tidrug-resistant tuberculosis. Lancet 2004; 363:474.
ED Chan et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169:1103.
Centers for Disease Control and Prevention (CDC). Acquired rifamycin resistance in persons with advanced HIV disease being treat- ed for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep 2002; 51:214.
RE Nettles et al. Risk factors for relapse and acquired rifamycin resist- ance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38:731.
W Manosuthi et al. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 2006; 53:357.
SA Shelburne et al. Incidence and risk factors for immune reconstitu- tion inflammatory syndrome during highly active antiretroviral thera- py. AIDS 2005; 14:399.
G Breton et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initia- tion of antiretroviral therapy. Clin Infect Dis 2004; 39:1709.
Centers for Disease Control and Prevention (CDC). Updated guide- lines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. Available at www.cdc.gov/nchstp/tb/ tb_hiv_drugs/toc.htm. Accessed February 13, 2007.
G Bothamley. Drug treatment for tuberculosis during pregnancy: safety considerations. Drug Saf 2001; 24:553.
S Shin et al. Treatment of multidrug-resistant tuberculosis during preg- nancy: a report of 7 cases. Clin Infect Dis 2003; 36:996.
KD Lessnau and S Qarah. Multidrug-resistant tuberculosis in pregnan- cy: case report and review of the literature. Chest 2003; 123:953.
PC Drobac et al. Treatment of multidrug-resistant tuberculosis during pregnancy: long-term follow-up of 6 children with intrauterine expo- sure to second-line agents. Clin Infect Dis 2005; 40:1689.
Medical Letter Adverse Drug Interactions Program.
World Health Organization. Ethambutol efficacy and toxicity: litera- ture review and recommendations for daily and intermittent dosage in children. Available at http://whqlibdoc.who.int/hq/2006/who_htm_ tb_2006.365_eng.pdf, Accessed February 13, 2007.
Also available from THE MEDICAL LETTER:
The Medical Letter on Drugs and Therapeutics is an independent, nonprofit newsletter offering unbiased, critical evaluations of drugs to healthcare professionals worldwide. Biweekly, 26 issues per year. Subscription includes print, full-text online access and Palm OS handheld application.
GROUP SITE LICENSE
The Medical Letter and Treatment Guidelines are available in a searchable format either by IP authentication or secure password login. For a free trial go to: http://medicalletter.org/html/institutions.htm or contact Gene Carbona at: 800-211-2769 x315 or email@example.com
Accredited by the ACCME, AAFP & ACPE
Available as a semi-annual exam in print or online, or as a per issue test with answers submitted online only.
Exams based on The Medical Letter content; earn up to 26 credits per year.
HANDBOOKS Handbook of Antimicrobial Therapy Drugs of Choice
Conclusions 2006: Excerpts from The Medical Letter
2006 edition of 2006 edition of
reatment Guidelines Bound Volume The Medical Letter Bound Volume
Coming Soon in Treatment Guidelines: Drugs for Pain – April 2007 Choice of Antibacterial Drugs – May 2007 Drugs for Cardiac Arrhythmias – June 2007
To subscribe, call (800) 211-2769 or visit online www.medicalletter.org
Mailing Address The Medical Lette , Inc. 1000 Main Street New Rochelle, NY 10801-7537
Customer Service Call: 800-211-2769 or 914-235-0500 M-F 8am-6pm Eastern Time Fax: 914-632-1733 Email: firstname.lastname@example.org
Web Site www.medicalletter.org
Back Issues Back issues are $12 each.
Subscriptions 1 year - $98; 2 years - $167; 3 years - $235. $49.00 per year for students, interns, residents and fellows in the US and Canada. All prices include print, full-text online access and handheld application.
Major credit cards accepted.
Bulk Subscriptions Special reduced rates for bulk subscriptions. Contact Customer Service at 800-211-2769. Special Classroom rates are available.
Site license inquires to: email@example.com or call 800-211-2769 x315
Permissions To reprint any portion of this issue, e-mail your request to: firstname.lastname@example.org.
Copyright and Disclaimer No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this pub- lication is accurate and complete in every respect. The editors shall not be held respon- sible for any damage resulting from any error, inaccuracy or omission.
The Medical Letter is an independent nonprofit organization that provides health care professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations. The editors declare no conflict of interest. The members of the Advisory Board are required to disclose any poten- tial conflict of interest.